腎線維症治療の世界市場レポート 2025年

腎線維症治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.7％で107億8,000万米ドルに成長します。予測期間の成長は、慢性腎臓病の有病率の増加、腎線維症管理のための先進治療に対する需要の高まり、早期腎線維症検出に対する意識の高まり、腎臓病治療における個別化医療の採用の高まり、糖尿病と高血圧の罹患率の増加などの要因によってもたらされます。予測期間における主な動向としては、早期発見・診断ツールの進歩、遺伝子治療の進歩、遠隔医療や遠隔モニタリングにおける技術の統合、幹細胞治療の進歩、ドラッグデリバリーシステムの革新などが挙げられます。

慢性腎臓病（CKD）の有病率の増加は、今後数年間の腎線維症治療市場の成長を牽引すると予想されます。CKDは進行性の腎機能低下であり、多くの場合、糖尿病や高血圧などの疾患によって引き起こされ、体内の老廃物の蓄積につながります。腎臓の血管を損傷し、老廃物を濾過する機能を損なう糖尿病の増加率は、CKDの増加に寄与する重要な要因です。腎線維症の治療は、腎組織の瘢痕化をターゲットとし、炎症を抑え、腎障害の進行を遅らせ、最終的には腎機能の維持に役立ちます。例えば、2024年5月、米国疾病予防管理センター（CDC）は、米国成人の約14％、約3,550万人が慢性腎臓病を患っていると報告しました。その結果、CKDの有病率の増加が腎線維症治療市場の拡大を牽引しています。

また、臨床試験の増加も腎線維症治療市場の成長を後押しすると予想されています。臨床試験とは、医療治療や介入の安全性、有効性、潜在的な副作用を評価するためにヒトを対象に実施される調査研究です。安全性と有効性を確保するために広範な試験を必要とする個別化治療や革新的治療に対する需要の高まりが、臨床試験の増加を促進しています。腎線維症治療は、新規の抗線維化療法を重点的に試験する領域を提供することで、これらの試験において重要な役割を果たしており、研究者は腎臓の損傷を遅らせたり、あるいは回復させたりする新薬の有効性を評価することができます。例えば、2023年11月、英国製薬工業協会（Association of the British Pharmaceutical Industry）は、英国における臨床試験の年間募集人数が15％増加し、2021-22年の3万6,722人から2022-23年には4万2,088人に増加すると報告しました。臨床試験が成長を続けるにつれ、腎線維症治療に対する需要も増加しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腎線維症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の腎線維症治療市場：成長率分析
• 世界の腎線維症治療市場の実績：規模と成長, 2019-2024
• 世界の腎線維症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界腎線維症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腎線維症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンジオテンシン変換酵素（ACE）阻害剤
• アンジオテンシンII受容体拮抗薬（ARB）
• ピルフェニドン
• レニン阻害剤
• 血管ペプチダーゼ阻害剤
• その他の治療の種類
• 世界の腎線維症治療市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 尿検査
• 画像検査
• 腎生検
• 世界の腎線維症治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性腎臓病
• 腎臓がんの治療
• その他の用途
• 世界の腎線維症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 研究センター
• 病院
• 世界の腎線維症治療市場アンジオテンシン変換酵素（ACE）阻害剤の治療タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エナラプリル
• カプトプリ
• リシノプリル
• ラミプリル
• 世界の腎線維症治療市場アンジオテンシンII受容体拮抗薬（ARB）の治療タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロサルタン
• テルミサルタン
• バルサルタン
• イルベサルタン
• 世界の腎線維症治療市場ピルフェニドンの治療タイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド名ピルフェニドン
• ジェネリックピルフェニドン
• 世界の腎線維症治療市場レニン阻害剤の治療タイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アリスキレン
• 実験的レニン阻害剤
• 世界の腎線維症治療市場血管ペプチダーゼ阻害剤の治療タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オマパトリラット
• サンパトリラット
• 世界の腎線維症治療市場、その他の治療タイプのサブセグメンテーション、治療タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗炎症剤
• 幹細胞療法
• 臨床試験中の抗線維化剤
• 遺伝子治療

第7章 地域別・国別分析

• 世界の腎線維症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腎線維症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腎線維症治療市場：競合情勢
• 腎線維症治療市場：企業プロファイル
  • F. Hoffman-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Cara Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Vertex Pharmaceuticals Incorporated
• Chinook Therapeutics Inc.
• Reata Pharmaceuticals Inc.
• Akebia Therapeutics Inc.
• Travere Therapeutics Inc.
• Insilico Medicine Inc.
• Tvardi Therapeutics Inc.
• ProKidney LLC
• Alentis Therapeutics AG
• La Jolla Pharmaceutical Company
• Galecto Biotech AB
• Purespring Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腎線維症治療市場2029：新たな機会を提供する国
• 腎線維症治療市場2029：新たな機会を提供するセグメント
• 腎線維症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Kidney fibrosis treatment refers to therapeutic approaches aimed at slowing, halting, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis is the excessive buildup of extracellular matrix proteins, such as collagen, leading to scarring and a decline in kidney function, commonly associated with chronic kidney disease (CKD).

The primary treatment types for kidney fibrosis include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), pirfenidone, renin inhibitors, vasopeptidase inhibitors, and others. ACE inhibitors help lower blood pressure and reduce heart strain by blocking the enzyme that converts angiotensin I into angiotensin II. Diagnosis involves blood and urine tests, imaging scans, and kidney biopsies. These treatments are used for chronic kidney diseases, kidney cancer, and other related conditions. They are applied by various end-users, such as clinics, research centers, and hospitals.

The kidney fibrosis treatment market research report is one of a series of new reports from The Business Research Company that provides kidney fibrosis treatment market statistics, including the kidney fibrosis treatment industry's global market size, regional shares, competitors with the kidney fibrosis treatment market share, detailed kidney fibrosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kidney fibrosis treatment market. This kidney fibrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kidney fibrosis treatment market size has grown strongly in recent years. It will grow from $6.93 billion in 2024 to $7.58 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historical period can be attributed to factors such as growing research and development investments in fibrosis-targeting therapies, increasing government funding for kidney disease management initiatives, rising patient awareness of kidney transplantation and fibrosis treatment options, the expansion of healthcare infrastructure, and the growing prevalence of aging populations.

The kidney fibrosis treatment market size is expected to see rapid growth in the next few years. It will grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The projected growth in the forecast period is driven by factors including the increasing prevalence of chronic kidney diseases, rising demand for advanced therapies for renal fibrosis management, growing awareness of early-stage kidney fibrosis detection, the rising adoption of personalized medicine in kidney disease treatment, and the increasing incidence of diabetes and hypertension. Key trends in the forecast period include advancements in early detection and diagnostic tools, progress in gene therapy, the integration of technology in telemedicine and remote monitoring, advancements in stem cell therapies, and innovations in drug delivery systems.

The growing prevalence of chronic kidney disease (CKD) is expected to drive the growth of the kidney fibrosis treatment market in the coming years. CKD is a progressive loss of kidney function, often caused by conditions such as diabetes or hypertension, which lead to the accumulation of waste products in the body. The increasing rates of diabetes, which damages kidney blood vessels and impairs their ability to filter waste, are a key factor contributing to the rise in CKD. Kidney fibrosis treatments target kidney tissue scarring, reduce inflammation, and slow the progression of kidney damage, ultimately helping to preserve kidney function. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that around 14% of U.S. adults, or approximately 35.5 million people, are living with chronic kidney disease. As a result, the growing prevalence of CKD is driving the expansion of the kidney fibrosis treatment market.

The increasing number of clinical trials is also expected to fuel the growth of the kidney fibrosis treatment market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and potential side effects of medical treatments or interventions. The rising demand for personalized and innovative therapies, which require extensive testing to ensure safety and efficacy, is driving the increase in clinical trials. Kidney fibrosis treatments play a crucial role in these trials by offering a focused area for testing novel anti-fibrotic therapies, enabling researchers to evaluate the effectiveness of new drugs in slowing or even reversing kidney damage. For instance, in November 2023, the Association of the British Pharmaceutical Industry reported a 15% increase in annual recruitment to clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. As clinical trials continue to grow, so too does the demand for kidney fibrosis treatments.

In May 2023, Chinook Therapeutics, a U.S.-based biotechnology company, partnered with Ionis Pharmaceuticals, another U.S.-based biotech firm, to develop a precision therapy for chronic kidney disease. This collaboration aims to create an antisense oligonucleotide therapy targeting the genetic causes of rare, severe forms of CKD, with the goal of improving patient outcomes and reducing the need for dialysis or kidney transplants. Ionis Pharmaceuticals is also developing therapies for kidney fibrosis, including IONIS-FB-LRx, a treatment for IgA nephropathy, further highlighting the push toward innovative treatments for CKD.

Major players in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the kidney fibrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney fibrosis treatment market includes revenues earned by entities by providing services such as pharmacological treatment, diagnostic and monitoring services, and lifestyle and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Fibrosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney fibrosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney fibrosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney fibrosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors; Angiotensin Ii Receptor Blockers (Arbs); Pirfenidone; Renin Inhibitors; Vasopeptidase Inhibitors; Other Treatment Types
• 2) By Diagnosis: Blood Tests; Urine Tests; Imaging Tests; Kidney Biopsy
• 3) By Application: Chronic Kidney Diseases; Kidney Cancer Treatment; Other Applications
• 4) By End-User: Clinics; Research Center; Hospitals
• Subsegments:
• 1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril; Captopri; Lisinopril; Ramipril
• 2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan; Telmisartan; Valsartan; Irbesartan
• 3) By Pirfenidone: Branded Pirfenidone; Generic Pirfenidone
• 4) By Renin Inhibitors: Aliskiren; Experimental Renin Inhibitors
• 5) By Vasopeptidase Inhibitors: Omapatrilat; Sampatrilat
• 6) By Other Treatment Types: Anti-Inflammatory Agents; Stem Cell Therapy; Antifibrotic Agents Under Clinical Trials; Gene Therapy
• Companies Mentioned: F. Hoffman-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; AstraZeneca PLC; Cara Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kidney Fibrosis Treatment Market Characteristics

3. Kidney Fibrosis Treatment Market Trends And Strategies

4. Kidney Fibrosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Kidney Fibrosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Kidney Fibrosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Kidney Fibrosis Treatment Market Growth Rate Analysis
• 5.4. Global Kidney Fibrosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Kidney Fibrosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Kidney Fibrosis Treatment Total Addressable Market (TAM)

6. Kidney Fibrosis Treatment Market Segmentation

• 6.1. Global Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin-Converting Enzyme (Ace) Inhibitors
• Angiotensin Ii Receptor Blockers (Arbs)
• Pirfenidone
• Renin Inhibitors
• Vasopeptidase Inhibitors
• Other Treatment Types
• 6.2. Global Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Urine Tests
• Imaging Tests
• Kidney Biopsy
• 6.3. Global Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Kidney Diseases
• Kidney Cancer Treatment
• Other Applications
• 6.4. Global Kidney Fibrosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Research Center
• Hospitals
• 6.5. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (Ace) Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enalapril
• Captopri
• Lisinopril
• Ramipril
• 6.6. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin Ii Receptor Blockers (Arbs), By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Losartan
• Telmisartan
• Valsartan
• Irbesartan
• 6.7. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Pirfenidone, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Pirfenidone
• Generic Pirfenidone
• 6.8. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Renin Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aliskiren
• Experimental Renin Inhibitors
• 6.9. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Vasopeptidase Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omapatrilat
• Sampatrilat
• 6.10. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Other Treatment Types, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Inflammatory Agents
• Stem Cell Therapy
• Antifibrotic Agents Under Clinical Trials
• Gene Therapy

7. Kidney Fibrosis Treatment Market Regional And Country Analysis

• 7.1. Global Kidney Fibrosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Kidney Fibrosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kidney Fibrosis Treatment Market

• 8.1. Asia-Pacific Kidney Fibrosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kidney Fibrosis Treatment Market

• 9.1. China Kidney Fibrosis Treatment Market Overview
• 9.2. China Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kidney Fibrosis Treatment Market

• 10.1. India Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kidney Fibrosis Treatment Market

• 11.1. Japan Kidney Fibrosis Treatment Market Overview
• 11.2. Japan Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kidney Fibrosis Treatment Market

• 12.1. Australia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kidney Fibrosis Treatment Market

• 13.1. Indonesia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kidney Fibrosis Treatment Market

• 14.1. South Korea Kidney Fibrosis Treatment Market Overview
• 14.2. South Korea Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kidney Fibrosis Treatment Market

• 15.1. Western Europe Kidney Fibrosis Treatment Market Overview
• 15.2. Western Europe Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kidney Fibrosis Treatment Market

• 16.1. UK Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kidney Fibrosis Treatment Market

• 17.1. Germany Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kidney Fibrosis Treatment Market

• 18.1. France Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kidney Fibrosis Treatment Market

• 19.1. Italy Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kidney Fibrosis Treatment Market

• 20.1. Spain Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kidney Fibrosis Treatment Market

• 21.1. Eastern Europe Kidney Fibrosis Treatment Market Overview
• 21.2. Eastern Europe Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kidney Fibrosis Treatment Market

• 22.1. Russia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kidney Fibrosis Treatment Market

• 23.1. North America Kidney Fibrosis Treatment Market Overview
• 23.2. North America Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kidney Fibrosis Treatment Market

• 24.1. USA Kidney Fibrosis Treatment Market Overview
• 24.2. USA Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kidney Fibrosis Treatment Market

• 25.1. Canada Kidney Fibrosis Treatment Market Overview
• 25.2. Canada Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kidney Fibrosis Treatment Market

• 26.1. South America Kidney Fibrosis Treatment Market Overview
• 26.2. South America Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kidney Fibrosis Treatment Market

• 27.1. Brazil Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kidney Fibrosis Treatment Market

• 28.1. Middle East Kidney Fibrosis Treatment Market Overview
• 28.2. Middle East Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kidney Fibrosis Treatment Market

• 29.1. Africa Kidney Fibrosis Treatment Market Overview
• 29.2. Africa Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kidney Fibrosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Kidney Fibrosis Treatment Market Competitive Landscape
• 30.2. Kidney Fibrosis Treatment Market Company Profiles
  • 30.2.1. F. Hoffman-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Cara Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Kidney Fibrosis Treatment Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Novo Nordisk A/S
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Vertex Pharmaceuticals Incorporated
• 31.5. Chinook Therapeutics Inc.
• 31.6. Reata Pharmaceuticals Inc.
• 31.7. Akebia Therapeutics Inc.
• 31.8. Travere Therapeutics Inc.
• 31.9. Insilico Medicine Inc.
• 31.10. Tvardi Therapeutics Inc.
• 31.11. ProKidney LLC
• 31.12. Alentis Therapeutics AG
• 31.13. La Jolla Pharmaceutical Company
• 31.14. Galecto Biotech AB
• 31.15. Purespring Therapeutics Inc.

32. Global Kidney Fibrosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kidney Fibrosis Treatment Market

34. Recent Developments In The Kidney Fibrosis Treatment Market

35. Kidney Fibrosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Kidney Fibrosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Kidney Fibrosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Kidney Fibrosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer